Ebrahimi-Nik, Hakimeh
Corwin, William L.
Shcheglova, Tatiana
Das Mohapatra, Alok
Mandoiu, Ion I.
Srivastava, Pramod K. http://orcid.org/0000-0003-2837-2861
Funding for this research was provided by:
Neag Cancer Immunology Translational Program
Northeastern Utilities Chair in Experimental Oncology
The Personalized Immunotherapy Core Interest Group of the Connecticut Institute for Clinical and Translational Science
SPARK award from University of Connecticut School of Medicine
Article History
Received: 18 January 2018
Accepted: 6 July 2018
First Online: 20 July 2018
Compliance with ethical standards
:
: Pramod K. Srivastava has a significant financial interest in Truvax Inc., which has rights to the technology described in this paper. The rest of the authors declare that they have no conflict of interest.
: All animal studies were performed with permission from the Institutional Animal Care and Use Committee of the University of Connecticut Health Center (Farmington, Connecticut) (Protocol number 101350-0619) and were in compliance with established guidelines. Mice were killed with CO2immediately after showing any sign of discomfort or if the average tumor size reached 15 mm.